| Bioactivity | IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. | ||||||||||||
| Target | IC50: 7 nM (IRAK4) | ||||||||||||
| Invitro | The in vitro metabolic stability profiles of IRAK4-IN-1 (Compound 23) is measured, with EC50 of 2300 nM for the rat whole blood (RWB) [1]. | ||||||||||||
| In Vivo | Oral pharmacokinetic studies of IRAK4-IN-1 (Compound 23) show it to have high bioavailability of 73% and low plasma clearance(Clp=22 mL/min/kg) leading to a reasonable half-life of 1.3 h[1]. | ||||||||||||
| Name | IRAK4-IN-1 | ||||||||||||
| CAS | 1820787-94-7 | ||||||||||||
| Formula | C19H23N5O | ||||||||||||
| Molar Mass | 337.42 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Smith GF, et al. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726. |